Mapping Patterns of Para-Aortic Recurrence Following Treatment for Cervical Cancer: Implications for Para-Aortic Clinical Target Volume

Abstract

toxicity. In terms of long-term adverse effects, there was no statistically significant difference between two groups no matter for bladder or vaginal complications. Conclusion: For patients with stage IIA-IIIA cervical cancer, NACT+ RS did not show an improvement on survival outcomes or long-term adverse effects compared with CCRT. It needs more randomized trials to investigate its role in locally advanced cervical cancer.